Travere Therapeutics (TVTX) News Today $14.52 -0.61 (-4.03%) Closing price 04:00 PM EasternExtended Trading$14.54 +0.02 (+0.11%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Why is Travere Therapeutics Dropping Today?Travere Therapeutics, Inc. (NASDAQ:TVTX) saw its stock price increase today amid a mix of analyst actions, corporate updates, and legal developments impacting investor sentiment. Cantor Fitzgerald raised its FY2026 EPS estimate to $1.86 (versus a consensus of –$1.40) and maintained an Overweight rating on TVTX. HC Wainwright initiated coverage with a Buy rating and set a $30.00 price target, implying over 100% upside from current levels. Travere announced it will present new FILSPARI® (sparsentan) data at the 15th International Podocyte Conference, underscoring progress in its rare-disease pipeline. Citigroup trimmed its price target from $35.00 to $32.00 but kept a Buy rating on the stock. The company launched a “Play It Forward” campaign for FSGS awareness, enhancing its patient-focused outreach. Short interest remains at zero shares, indicating minimal bearish pressure in the market. Pomerantz LLP announced an investigation into potential claims on behalf of Travere investors, raising legal risk concerns. Investors will be watching upcoming clinical readouts, analyst guidance, and any developments in the legal inquiry to gauge the stock’s trajectory.Posted 2h agoAI Generated. May Contain Errors. TVTX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Cantor Fitzgerald Predicts TVTX FY2026 EarningsTravere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Travere Therapeutics in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal expects that the company will post earnJune 11 at 8:45 AM | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Given "Buy" Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $30.00 price target on shares of Travere Therapeutics in a research report on Wednesday.June 11 at 8:24 AM | marketbeat.comCitigroup Issues Pessimistic Forecast for Travere Therapeutics (NASDAQ:TVTX) Stock PriceCitigroup cut their price objective on shares of Travere Therapeutics from $35.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday.June 11 at 8:24 AM | marketbeat.comTravere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte ConferenceJune 11 at 7:01 AM | businesswire.comTravere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness DayJune 10 at 9:57 AM | finance.yahoo.comWellington Management Group LLP Invests $583,000 in Travere Therapeutics, Inc. (NASDAQ:TVTX)Wellington Management Group LLP bought a new stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 33,493 shares of the company's stocJune 8 at 3:48 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXJune 7, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXJune 6, 2025 | globenewswire.comTravere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA CongressJune 3, 2025 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXJune 2, 2025 | globenewswire.comUniversal Beteiligungs und Servicegesellschaft mbH Buys New Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 253,622 shares ofJune 2, 2025 | marketbeat.comPublic Employees Retirement System of Ohio Raises Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Public Employees Retirement System of Ohio lifted its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 102.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 102,756 shares of the company'June 2, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXJune 1, 2025 | prnewswire.comAnalysts Set Travere Therapeutics, Inc. (NASDAQ:TVTX) PT at $31.79June 1, 2025 | americanbankingnews.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the fifteen brokerages that are covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and thirteen have isMay 30, 2025 | marketbeat.comTwo Sigma Investments LP Purchases 332,933 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Two Sigma Investments LP grew its position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 92.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 693,016 shares of the company's stockMay 26, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Stock Position Raised by Man Group plcMan Group plc lifted its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 246.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 88,241 shares of the company's stock after buying aMay 26, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Shares Bought by Millennium Management LLCMillennium Management LLC grew its position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 446.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 626,056 shares of the company's stock after acquiring an additionalMay 26, 2025 | marketbeat.comAmeriprise Financial Inc. Purchases 162,649 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Ameriprise Financial Inc. grew its position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 132.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 285,350 shares of the company's stock after purchasinMay 26, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Stock Holdings Lifted by Voloridge Investment Management LLCVoloridge Investment Management LLC lifted its position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 33.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,007,197 shMay 25, 2025 | marketbeat.comTwo Sigma Advisers LP Grows Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)Two Sigma Advisers LP grew its position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 34.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 967,500 shares of the company's stock after acquiring an additional 247,100 shares duMay 24, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Nuveen Asset Management LLCNuveen Asset Management LLC lessened its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 4.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,743,190 shares of the company's stock after selling 88May 24, 2025 | marketbeat.comWoodline Partners LP Has $36.83 Million Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)Woodline Partners LP decreased its position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 51.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,114,056 shares of the company's stockMay 23, 2025 | marketbeat.comTravere Therapeutics’ SWOT analysis: stock outlook amid regulatory reviewMay 21, 2025 | investing.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Shares Acquired by Rafferty Asset Management LLCRafferty Asset Management LLC boosted its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 92.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 176,425 shares of the companMay 21, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXMay 20, 2025 | prnewswire.comTravere Therapeutics: Establishing A Position After Last Week's SelloffMay 20, 2025 | seekingalpha.comDeutsche Bank AG Lowers Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)Deutsche Bank AG lessened its holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 24.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 532,031 shares of the company's stock after sellingMay 19, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Reduces Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)The Manufacturers Life Insurance Company decreased its position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 41.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,338 shares of the companMay 19, 2025 | marketbeat.comSphera Funds Management LTD. Increases Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Sphera Funds Management LTD. boosted its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 29.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 220,700 shares of the companMay 18, 2025 | marketbeat.comNorthern Trust Corp Has $13.14 Million Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Northern Trust Corp grew its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 11.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 754,395 shares of the company's stock afMay 18, 2025 | marketbeat.comTravere Therapeutics stock falls on FDA review setbackMay 16, 2025 | in.investing.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Shares Purchased by Parkman Healthcare Partners LLCParkman Healthcare Partners LLC raised its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 2.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,117,792 shares of the company's stock after buying an additioMay 16, 2025 | marketbeat.comTravere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGSMay 15, 2025 | businesswire.comAlgert Global LLC Invests $282,000 in Travere Therapeutics, Inc. (NASDAQ:TVTX)Algert Global LLC purchased a new stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 16,167 shares of the company's stock, valued at approximately $2May 15, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Stock Position Reduced by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD lessened its position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 85.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 39,604 shares of the comMay 15, 2025 | marketbeat.comIntegral Health Asset Management LLC Buys New Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Integral Health Asset Management LLC bought a new stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 100,000 shares oMay 14, 2025 | marketbeat.comJ. Goldman & Co LP Makes New Investment in Travere Therapeutics, Inc. (NASDAQ:TVTX)J. Goldman & Co LP purchased a new position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 181,174 shares of the company's stock, valued at approxiMay 14, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Has $37.88 Million Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Jacobs Levy Equity Management Inc. grew its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 36.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,174,213 shares of the company's stock afMay 14, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Sells 152,820 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Schonfeld Strategic Advisors LLC cut its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 86.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,000 shares of the company's stock after selling 152,May 13, 2025 | marketbeat.comTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 12, 2025 | businesswire.comBrevan Howard Capital Management LP Sells 30,742 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Brevan Howard Capital Management LP decreased its position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 49.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 30,953 shares of the compMay 12, 2025 | marketbeat.com1,209,810 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Purchased by BNP Paribas Financial MarketsBNP Paribas Financial Markets bought a new stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 1,209,810 shares of the company's stock, valued at approximately $21,075,000. BNP Paribas Financial MaMay 12, 2025 | marketbeat.comDriehaus Capital Management LLC Has $38.64 Million Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)Driehaus Capital Management LLC increased its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 608.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,217,975May 11, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Shares Acquired by Crestline Management LPCrestline Management LP increased its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 53.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 185,840 shares of the company's stock after acquMay 10, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Stake Boosted by AQR Capital Management LLCAQR Capital Management LLC boosted its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 117.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 424,024 shares of the company's stock after purchasMay 10, 2025 | marketbeat.comHsbc Holdings PLC Has $487,000 Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)Hsbc Holdings PLC reduced its position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 33.4% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 27,835 shares of the company's stock after selling 13,981 shares during the period. Hsbc Holdings PLC's holdMay 9, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Insider Sells $37,279.55 in StockTravere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Peter Heerma sold 1,771 shares of Travere Therapeutics stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $21.05, for a total value of $37,279.55. Following the completion of the transaction, the insider now owns 128,215 shares of the company's stock, valued at approximately $2,698,925.75. The trade was a 1.36 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.May 8, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) CFO Sells $37,553.20 in StockTravere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CFO Christopher R. Cline sold 1,784 shares of the stock in a transaction on Monday, May 5th. The shares were sold at an average price of $21.05, for a total value of $37,553.20. Following the transaction, the chief financial officer now directly owns 93,126 shares of the company's stock, valued at approximately $1,960,302.30. The trade was a 1.88 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.May 8, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) CEO Sells $398,350.20 in StockTravere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CEO Eric M. Dube sold 18,924 shares of the firm's stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $21.05, for a total transaction of $398,350.20. Following the sale, the chief executive officer now owns 419,173 shares in the company, valued at approximately $8,823,591.65. The trade was a 4.32 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.May 8, 2025 | marketbeat.com Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address TVTX Media Mentions By Week TVTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TVTX News Sentiment▼0.561.01▲Average Medical News Sentiment TVTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TVTX Articles This Week▼127▲TVTX Articles Average Week Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ADMA Biologics News Today Vaxcyte News Today Akero Therapeutics News Today Rhythm Pharmaceuticals News Today Zai Lab News Today PTC Therapeutics News Today Cytokinetics News Today Avidity Biosciences News Today Krystal Biotech News Today Sarepta Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TVTX) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TVTX Stock Free TVTX Stock Alerts